Dr. Elizabeth Hulme Berezovsky is a Harvard-trained R&D leader with a passion for transforming innovative discoveries into treatments and cures for human disease.  Most recently, she was Director of Technical Operations at BioMotiv, a mission-driven drug development accelerator in Cleveland, Ohio, where she oversaw R&D operations for BioMotiv’s portfolio of drug development start-ups.  She directed development at two BioMotiv subsidiary companies: Allinaire Therapeutics, an early-stage company developing treatment for COPD and other pulmonary diseases; and SapVax, a cancer vaccine platform company.

Dr. Berezovsky was an NIH Ruth L. Kirschstein NRSA Post-Doctoral Fellow at the Cleveland Clinic in the Department of Molecular Genetics.  She received her Ph.D. in chemistry under the direction of Professor George M. Whitesides at Harvard University, and holds an undergraduate degree in chemistry from McGill University.